[
    {
        "headline": "Q1 Earnings Highs And Lows: Avantor (NYSE:AVTR) Vs The Rest Of The Research Tools & Consumables Stocks",
        "text": "Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Avantor (NYSE:AVTR) and the best and worst performers in the research tools & consumables industry."
    },
    {
        "headline": "Danaher Corporation (DHR): Among Billionaire Lei Zhang’s Stock Picks with Huge Upside Potential",
        "text": "We recently published a list of Billionaire Lei Zhang’s 10 Stock Picks with Huge Upside Potential. In this article, we are going to take a look at where Danaher Corporation (NYSE:DHR) stands against other billionaire Lei Zhang’s stock picks with huge upside potential. Lei Zhang and Hillhouse Capital: Quiet Power in Asian Investing Lei Zhang, […]"
    },
    {
        "headline": "CVS vs. DHR: Which Stock Is the Better Value Option?",
        "text": "CVS vs. DHR: Which Stock Is the Better Value Option?"
    },
    {
        "headline": "Is Danaher Corporation (DHR) the Best Medical Device Stock to Buy Now?",
        "text": "We recently published a list of 11 Best Medical Device Stocks to Buy Now. In this article, we are going to take a look at where Danaher Corporation (NYSE:DHR) stands against other best medical device stocks to buy now. Trump’s Tariffs Are Dividing the Medical Community On April 16, CNBC reported that Trump’s tariffs are […]"
    },
    {
        "headline": "1 S&P 500 Stock with Competitive Advantages and 2 to Keep Off Your Radar",
        "text": "The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all large-cap stocks are created equal - some are struggling with slowing growth, declining margins, or increased competition."
    },
    {
        "headline": "Spotting Winners: Sotera Health Company (NASDAQ:SHC) And Research Tools & Consumables Stocks In Q1",
        "text": "The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how research tools & consumables stocks fared in Q1, starting with Sotera Health Company (NASDAQ:SHC)."
    },
    {
        "headline": "From Apple to GM, Tariffs to Cost Companies Tens of Billions",
        "text": "(Bloomberg) -- From Apple Inc. to General Motors Co., corporate America is bracing for tens of billions of dollars in damages from Trump’s trade war — and that’s before most affected goods have landed.Most Read from BloombergIs Trump’s Plan to Reopen the Notorious Alcatraz Prison Realistic?As Trump Reshapes Housing Policy, Renters Face Rollback of RightsVail to Borrow Muni Debt to Ease Ski Resort Town Housing CrunchNYC Warns of 17% Drop in Foreign Tourists Due to Trump PoliciesLA Mayor Credits T"
    },
    {
        "headline": "Danaher to Present at Bank of America Securities Healthcare Conference",
        "text": "Danaher Corporation (NYSE: DHR) announced that President and Chief Executive Officer, Rainer M. Blair, will be presenting at the at the Bank of America Securities Health Care Conference in Las Vegas, Nevada on Thursday, May 15, 2025 at 10:00 a.m. PT. The event will be simultaneously webcast on www.danaher.com."
    },
    {
        "headline": "Danaher (NYSE:DHR) Declares US$0.32 Quarterly Dividend Payment",
        "text": "Danaher (NYSE:DHR) recently affirmed a quarterly dividend of $0.32 per share, set for payout in July. Over the past month, the company's share price rose by 5%, reflecting a positive market response amid mixed broader market trends, as the Dow Jones and other indices showed varied movements tied to economic policies and earnings reports. Despite a decline in Q1 earnings and a buyback update, the dividend announcement likely added favorable sentiment towards Danaher's stock. This period's..."
    },
    {
        "headline": "Danaher Corporation (DHR): A Bull Case Theory",
        "text": "We came across a bullish thesis on Danaher Corporation (DHR) on Substack by Best Anchor Stocks. In this article, we will summarize the bulls’ thesis on DHR. Danaher Corporation (DHR)’s share was trading at $196.71 as of May 1st. DHR’s trailing and forward P/E were 38.12 and 25.64 respectively according to Yahoo Finance. Danaher recently reported a […]"
    },
    {
        "headline": "Danaher Announces Quarterly Dividend",
        "text": "Danaher Corporation (NYSE: DHR) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.32 per share of its common stock, payable on July 25, 2025 to holders of record on June 27, 2025."
    },
    {
        "headline": "Danaher Corporation (DHR): Among Charles Akre’s and John Neff’s Stock Picks With Huge Upside Potential",
        "text": "We recently published an article titled Charles Akre’s and John Neff’s 10 Stock Picks with Huge Upside Potential. In this article, we are going to take a look at where Danaher Corporation (NYSE:DHR) stands against the other stocks with huge upside potential according to Charles Akre and John Neff. The current market environment of the […]"
    },
    {
        "headline": "Kytopen and Aldevron Expedite Cell Therapy Manufacturing Through Their Collaborative CRISPR-mediated Cellular Engineering Workflow",
        "text": "Kytopen Corp., a leader in providing non-viral, continuous flow cellular engineering technologies and Aldevron, a leading global manufacturer serving organizations in the gene editing, mRNA vaccine and therapeutics, viral gene therapy, and modified gene therapy spaces; today announced, a joint marketing agreement aimed at enhancing the workflow solutions for cell therapy manufacturers. The collaboration will focus on the joint promotion of the synergies achieved by combining the Aldveron Nanopla"
    },
    {
        "headline": "Jim Cramer on Danaher Corporation (DHR): From Best to Worst Amid China Struggles",
        "text": "We recently published a list of Jim Cramer Talks About Elon Musk & Discusses These 11 Stocks. In this article, we are going to take a look at where Danaher Corporation (NYSE:DHR) stands against other stocks that Jim Cramer recently discussed. In a recent appearance on CNBC’s Squawk on the Street, Jim Cramer commented that […]"
    },
    {
        "headline": "Danaher Corporation (DHR): Among Billionaire Ken Fisher’s Healthcare Stock Picks with Massive Upside Potential",
        "text": "We recently published a list of Billionaire Ken Fisher’s 10 Healthcare Stock Picks with Massive Upside Potential. In this article, we are going to take a look at where Danaher Corporation (NYSE:DHR) stands against other billionaire Ken Fisher’s healthcare stock picks with massive upside potential. The healthcare industry, an essential component of global well-being and […]"
    },
    {
        "headline": "Danaher predicts $350M tariff hit, moves to mitigate impact on profits",
        "text": "The company is planning manufacturing footprint changes, supply chain adjustments, surcharges and cost cutting to limit the impact of the tariffs."
    },
    {
        "headline": "Danaher price target lowered to $240 from $260 at Goldman Sachs",
        "text": "Goldman Sachs analyst Matthew Sykes lowered the firm’s price target on Danaher (DHR) to $240 from $260 but keeps a Buy rating on the shares after its Q1 results. The company’s Bioprocessing business continues to improve, and the current tariff headwind appears manageable, the analyst tells investors in a research note. Despite the top and bottom line beat in the quarter however, there is still merit in the prudent approach with Danaher maintaining prior FY25 guidance given all the moving parts a"
    },
    {
        "headline": "Danaher Corporation (DHR): Among Top Stocks in Bill Gates’ Portfolio with Huge Upside Potential",
        "text": "We recently published a list of Bill Gates’ 10 Stock Positions with Huge Upside Potential. In this article, we are going to take a look at where Danaher Corporation (NYSE:DHR) stands against other top stocks in Bill Gates’ portfolio with huge upside potential. Bill Gates became the youngest billionaire back in 1987 when he took […]"
    },
    {
        "headline": "BLCO or DHR: Which Is the Better Value Stock Right Now?",
        "text": "BLCO vs. DHR: Which Stock Is the Better Value Option?"
    },
    {
        "headline": "Danaher First Quarter 2025 Earnings: Beats Expectations",
        "text": "Danaher ( NYSE:DHR ) First Quarter 2025 Results Key Financial Results Revenue: US$5.74b (flat on 1Q 2024). Net income..."
    },
    {
        "headline": "Q1 Earnings Highs And Lows: Avantor (NYSE:AVTR) Vs The Rest Of The Research Tools & Consumables Stocks",
        "text": "Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Avantor (NYSE:AVTR) and the best and worst performers in the research tools & consumables industry."
    },
    {
        "headline": "Danaher Corporation (DHR): Among Billionaire Lei Zhang’s Stock Picks with Huge Upside Potential",
        "text": "We recently published a list of Billionaire Lei Zhang’s 10 Stock Picks with Huge Upside Potential. In this article, we are going to take a look at where Danaher Corporation (NYSE:DHR) stands against other billionaire Lei Zhang’s stock picks with huge upside potential. Lei Zhang and Hillhouse Capital: Quiet Power in Asian Investing Lei Zhang, […]"
    },
    {
        "headline": "CVS vs. DHR: Which Stock Is the Better Value Option?",
        "text": "CVS vs. DHR: Which Stock Is the Better Value Option?"
    },
    {
        "headline": "Is Danaher Corporation (DHR) the Best Medical Device Stock to Buy Now?",
        "text": "We recently published a list of 11 Best Medical Device Stocks to Buy Now. In this article, we are going to take a look at where Danaher Corporation (NYSE:DHR) stands against other best medical device stocks to buy now. Trump’s Tariffs Are Dividing the Medical Community On April 16, CNBC reported that Trump’s tariffs are […]"
    },
    {
        "headline": "1 S&P 500 Stock with Competitive Advantages and 2 to Keep Off Your Radar",
        "text": "The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all large-cap stocks are created equal - some are struggling with slowing growth, declining margins, or increased competition."
    },
    {
        "headline": "Spotting Winners: Sotera Health Company (NASDAQ:SHC) And Research Tools & Consumables Stocks In Q1",
        "text": "The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how research tools & consumables stocks fared in Q1, starting with Sotera Health Company (NASDAQ:SHC)."
    },
    {
        "headline": "From Apple to GM, Tariffs to Cost Companies Tens of Billions",
        "text": "(Bloomberg) -- From Apple Inc. to General Motors Co., corporate America is bracing for tens of billions of dollars in damages from Trump’s trade war — and that’s before most affected goods have landed.Most Read from BloombergIs Trump’s Plan to Reopen the Notorious Alcatraz Prison Realistic?As Trump Reshapes Housing Policy, Renters Face Rollback of RightsVail to Borrow Muni Debt to Ease Ski Resort Town Housing CrunchNYC Warns of 17% Drop in Foreign Tourists Due to Trump PoliciesLA Mayor Credits T"
    },
    {
        "headline": "Danaher to Present at Bank of America Securities Healthcare Conference",
        "text": "Danaher Corporation (NYSE: DHR) announced that President and Chief Executive Officer, Rainer M. Blair, will be presenting at the at the Bank of America Securities Health Care Conference in Las Vegas, Nevada on Thursday, May 15, 2025 at 10:00 a.m. PT. The event will be simultaneously webcast on www.danaher.com."
    },
    {
        "headline": "Danaher (NYSE:DHR) Declares US$0.32 Quarterly Dividend Payment",
        "text": "Danaher (NYSE:DHR) recently affirmed a quarterly dividend of $0.32 per share, set for payout in July. Over the past month, the company's share price rose by 5%, reflecting a positive market response amid mixed broader market trends, as the Dow Jones and other indices showed varied movements tied to economic policies and earnings reports. Despite a decline in Q1 earnings and a buyback update, the dividend announcement likely added favorable sentiment towards Danaher's stock. This period's..."
    },
    {
        "headline": "Danaher Corporation (DHR): A Bull Case Theory",
        "text": "We came across a bullish thesis on Danaher Corporation (DHR) on Substack by Best Anchor Stocks. In this article, we will summarize the bulls’ thesis on DHR. Danaher Corporation (DHR)’s share was trading at $196.71 as of May 1st. DHR’s trailing and forward P/E were 38.12 and 25.64 respectively according to Yahoo Finance. Danaher recently reported a […]"
    },
    {
        "headline": "Danaher Announces Quarterly Dividend",
        "text": "Danaher Corporation (NYSE: DHR) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.32 per share of its common stock, payable on July 25, 2025 to holders of record on June 27, 2025."
    },
    {
        "headline": "Danaher Corporation (DHR): Among Charles Akre’s and John Neff’s Stock Picks With Huge Upside Potential",
        "text": "We recently published an article titled Charles Akre’s and John Neff’s 10 Stock Picks with Huge Upside Potential. In this article, we are going to take a look at where Danaher Corporation (NYSE:DHR) stands against the other stocks with huge upside potential according to Charles Akre and John Neff. The current market environment of the […]"
    },
    {
        "headline": "Kytopen and Aldevron Expedite Cell Therapy Manufacturing Through Their Collaborative CRISPR-mediated Cellular Engineering Workflow",
        "text": "Kytopen Corp., a leader in providing non-viral, continuous flow cellular engineering technologies and Aldevron, a leading global manufacturer serving organizations in the gene editing, mRNA vaccine and therapeutics, viral gene therapy, and modified gene therapy spaces; today announced, a joint marketing agreement aimed at enhancing the workflow solutions for cell therapy manufacturers. The collaboration will focus on the joint promotion of the synergies achieved by combining the Aldveron Nanopla"
    },
    {
        "headline": "Jim Cramer on Danaher Corporation (DHR): From Best to Worst Amid China Struggles",
        "text": "We recently published a list of Jim Cramer Talks About Elon Musk & Discusses These 11 Stocks. In this article, we are going to take a look at where Danaher Corporation (NYSE:DHR) stands against other stocks that Jim Cramer recently discussed. In a recent appearance on CNBC’s Squawk on the Street, Jim Cramer commented that […]"
    },
    {
        "headline": "Danaher Corporation (DHR): Among Billionaire Ken Fisher’s Healthcare Stock Picks with Massive Upside Potential",
        "text": "We recently published a list of Billionaire Ken Fisher’s 10 Healthcare Stock Picks with Massive Upside Potential. In this article, we are going to take a look at where Danaher Corporation (NYSE:DHR) stands against other billionaire Ken Fisher’s healthcare stock picks with massive upside potential. The healthcare industry, an essential component of global well-being and […]"
    },
    {
        "headline": "Danaher predicts $350M tariff hit, moves to mitigate impact on profits",
        "text": "The company is planning manufacturing footprint changes, supply chain adjustments, surcharges and cost cutting to limit the impact of the tariffs."
    },
    {
        "headline": "Danaher price target lowered to $240 from $260 at Goldman Sachs",
        "text": "Goldman Sachs analyst Matthew Sykes lowered the firm’s price target on Danaher (DHR) to $240 from $260 but keeps a Buy rating on the shares after its Q1 results. The company’s Bioprocessing business continues to improve, and the current tariff headwind appears manageable, the analyst tells investors in a research note. Despite the top and bottom line beat in the quarter however, there is still merit in the prudent approach with Danaher maintaining prior FY25 guidance given all the moving parts a"
    },
    {
        "headline": "Danaher Corporation (DHR): Among Top Stocks in Bill Gates’ Portfolio with Huge Upside Potential",
        "text": "We recently published a list of Bill Gates’ 10 Stock Positions with Huge Upside Potential. In this article, we are going to take a look at where Danaher Corporation (NYSE:DHR) stands against other top stocks in Bill Gates’ portfolio with huge upside potential. Bill Gates became the youngest billionaire back in 1987 when he took […]"
    },
    {
        "headline": "BLCO or DHR: Which Is the Better Value Stock Right Now?",
        "text": "BLCO vs. DHR: Which Stock Is the Better Value Option?"
    },
    {
        "headline": "Danaher First Quarter 2025 Earnings: Beats Expectations",
        "text": "Danaher ( NYSE:DHR ) First Quarter 2025 Results Key Financial Results Revenue: US$5.74b (flat on 1Q 2024). Net income..."
    },
    {
        "headline": "Danaher Corp (DHR) Q1 2025 Earnings Call Highlights: Strong Bioprocessing Growth Amidst Mixed ...",
        "text": "Danaher Corp (DHR) reports robust bioprocessing growth and improved profitability, despite challenges in Life Sciences and Diagnostics segments."
    },
    {
        "headline": "Q1 2025 Danaher Corp Earnings Call",
        "text": "Q1 2025 Danaher Corp Earnings Call"
    },
    {
        "headline": "DHR Q1 Earnings: Bioprocessing Momentum and Tariff Strategy Drive Guidance Above Expectations",
        "text": "Diversified science and technology company Danaher (NYSE:DHR) announced better-than-expected revenue in Q1 CY2025, but sales were flat year on year at $5.74 billion. Guidance for next quarter’s revenue was better than expected at $5.92 billion at the midpoint, 1.4% above analysts’ estimates. Its non-GAAP profit of $1.88 per share was 14.4% above analysts’ consensus estimates."
    },
    {
        "headline": "S&P Behemoth Danaher Surges On Plans To Navigate Pharma-Tied Tariffs",
        "text": "Danaher stock jumped Tuesday after the medical powerhouse delivered a \"solid\" first-quarter report and maintained its outlook for the year."
    },
    {
        "headline": "Danaher (DHR) Stock Trades Up, Here Is Why",
        "text": "Shares of diversified science and technology company Danaher (NYSE:DHR) jumped 6.6% in the afternoon session after the company reported impressive first quarter 2025 results, which beat analysts' organic revenue and EPS expectations. Revenue was flat year-over-year on a core basis, which masked a 7% gain in biotech and a modest decline in life sciences, revealing the uneven recovery across business lines. Looking ahead, sales guidance for the next quarter was ahead, while full year EPS guidance"
    },
    {
        "headline": "Danaher Q1 Earnings Beat Estimates, Life Sciences Sales Down Y/Y",
        "text": "DHR's first-quarter sales decrease 1% year over year, due to the lackluster performance of its Life Sciences and Biotechnology segments."
    },
    {
        "headline": "Danaher Fiscal First-Quarter Results Top Views; Forecasts Core Revenue Growth",
        "text": "Danaher (DHR) on Tuesday reported better-than-expected fiscal first-quarter results, while the medic"
    },
    {
        "headline": "Danaher (DHR) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates",
        "text": "The headline numbers for Danaher (DHR) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals."
    },
    {
        "headline": "Danaher (DHR) Surpasses Q1 Earnings and Revenue Estimates",
        "text": "Danaher (DHR) delivered earnings and revenue surprises of 16.05% and 3.34%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?"
    },
    {
        "headline": "Danaher (NYSE:DHR) Surprises With Q1 Sales, Next Quarter’s Sales Guidance is Optimistic",
        "text": "Diversified science and technology company Danaher (NYSE:DHR) reported Q1 CY2025 results beating Wall Street’s revenue expectations, but sales were flat year on year at $5.74 billion. Guidance for next quarter’s revenue was better than expected at $5.92 billion at the midpoint, 1.9% above analysts’ estimates. Its non-GAAP profit of $1.88 per share was 14.4% above analysts’ consensus estimates."
    },
    {
        "headline": "Danaher: Q1 Earnings Snapshot",
        "text": "WASHINGTON (AP) — Danaher Corp. DHR) on Tuesday reported first-quarter profit of $954 million. The Washington-based company said it had profit of $1.32 per share."
    },
    {
        "headline": "Danaher Reports First Quarter 2025 Results",
        "text": "Danaher Corporation (NYSE: DHR) (the \"Company\") today announced results for the quarter ended March 28, 2025."
    },
    {
        "headline": "Danaher Gears Up to Post Q1 Earnings: Is a Beat in Store?",
        "text": "DHR's first-quarter earnings are likely to have been aided by strength in the Biotechnology segment. However, weakness in the Diagnostics and Life Sciences segments are expected to have hurt."
    },
    {
        "headline": "Danaher (DHR) To Report Earnings Tomorrow: Here Is What To Expect",
        "text": "Diversified science and technology company Danaher (NYSE:DHR) will be announcing earnings results tomorrow morning. Here’s what to look for."
    },
    {
        "headline": "2 of Wall Street’s Favorite Stocks with Competitive Advantages and 1 to Be Wary Of",
        "text": "Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts."
    }
]